StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Friday. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

TNXP opened at $0.48 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.87 and a current ratio of 1.47. The stock has a market capitalization of $1.43 million, a PE ratio of 0.00 and a beta of 2.12. The stock’s 50 day moving average price is $1.11 and its 200-day moving average price is $5.76. Tonix Pharmaceuticals has a 52-week low of $0.42 and a 52-week high of $32.32.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, May 13th. The company reported ($5.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($16.64) by $10.88. The company had revenue of $2.48 million for the quarter, compared to analysts’ expectations of $4.00 million. On average, equities research analysts predict that Tonix Pharmaceuticals will post -34.73 EPS for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.